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Background: Cancer has continually been the leading cause of death worldwide for decades. Thus, scientists have
actively devoted themselves to studying cancer therapeutics. Doxorubicin is an efficient drug used in cancer therapy,
but also produces reactive oxygen species (ROS) that induce severe cytotoxicity against heart cells. Quercetin,
a plant-derived flavonoid, has been proven to contain potent antioxidant and anti-inflammatory properties. Thus,
this in vitro study investigated whether quercetin can decrease doxorubicin-induced cytotoxicity and promote cell
repair systems in cardiomyocyte H9C2 cells.
Results: Proteomic analysis and a cell biology assay were performed to investigate the quercetin-induced responses.
Our data demonstrated that quercetin treatment protects the cardiomyocytes in a doxorubicin-induced heart damage
model. Quercetin significantly facilitated cell survival by inhibiting cell apoptosis and maintaining cell morphology by
rearranging the cytoskeleton. Additionally, 2D-DIGE combined with MALDI-TOF MS analysis indicated that quercetin
might stimulate cardiomyocytes to repair damage after treating doxorubicin by modulating metabolic activation,
protein folding and cytoskeleton rearrangement.
Conclusion: Based on a review of the literature, this study is the first to report detailed protective mechanisms for
the action of quercetin against doxorubicin-induced cardiomyocyte toxicity based on in-depth cell biology and
proteomic analysis.
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Doxorubicin is a chemotherapy drug, commonly used in
various cancer treatments, such as breast cancer, lung can-
cer and several other carcinoma types [1-3]. The principal
mechanism of doxorubicin is chelating DNA, inhibiting
topoisomerase II and then producing free radicals to kill
cancer cells. Reported side effects of doxorubicin include
cardiotoxicity, comprising cardiomyopathy and ultimately
fatal congestive heart failure. Because myocardia are par-
ticularly sensitive to reactive oxygen species (ROS), cumu-
lative doxorubicin in vivo causes irreversible damage to
heart cells, thus restricting clinical use of this drug [4].
Although the specific causal mechanism of doxorubicin-
induced cardiotoxicity remains largely unclear, most of
the evidence has indicated that doxorubicin is reduced
to its semiquinone form by a mitochondria electron trans-
port system. The semiquinone subsequently reacts with* Correspondence: chouhc@mail.nhcue.edu.tw
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stated.oxygen, iron, and hydrogen peroxide to produce ROS
causing cell apoptosis and myocyte damage [5,6]. In
addition, global analysis of doxorubicin-induced cellular
oxidative stress has indicated that doxorubicin treatment
contributes to the over-expression of anti-oxidant proteins
such as glutathione reductase and peroxiredoxin in brain
cells, lung cells and heart cells [7-9].
Quercetin, a type of polyphenolic compound found
in various plant products, possesses anti-oxidant, anti-
proliferative, anti-inflammatory and anti-histamine prop-
erties. Several reports have indicated that quercetin exerts
protective effects on various cells, including myocytes, tes-
tes, renal cells and liver cells in ischemia and reperfusion
injury [10]. A study conducted in 1992 determined that
quercetin reduces the oxidative stress caused by ischemia
and reperfusion in cardiomyocytes by inhibiting the xanthine
dehydrogenase and xanthine oxidase system [11]. Several
reports have also indicated that quercetin and isorhamne-
tin scavenge ROS and inhibit the activation of ERK and
MAP kinase in ROS-induced cardiomyopathy [12,13]. Intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Figure 1 Effect of doxorubicin treatment on H9C2 cell viability.
H9C2 cells were treated with indicated concentrations of doxorubicin
from 3 independent experiments. Cell viability was determined by MTT
assay after 24 h exposure of doxorubicin. Each data point indicates
mean ± SD of triplicate values.
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augmented the effects of doxorubicin in highly invasive
breast cancer cells [14] and can protect cardiomyocytes
from doxorubicin-induced toxicity by chelating iron,
inducing antioxidant activity, and inhibiting carbonyl
reductase [15]. Regarding proteomic analysis, the results
also indicated that quercetin could down-regulate Ras
GTPase-activating-like proteins and heat shock protein-90
to reduce cell migratory ability and cell survival, respect-
ively, in malignant cancers [16,17]. Although quercetin
has been reported to play a role in protecting myocardial
cells from ischemia and reperfusion injury, its protective
mechanism remains unclear.
To investigate the role of quercetin in alleviating
doxorubicin-induced cardiotoxicity, we examined the pro-
tective ability of quercetin in doxorubicin-treated rat
cardiomyocytes by performing cell biological assays, such
as cell viability and apoptotic analysis, as well as a
quantitative proteomic analysis based on 2D-DIGE and
MALDI-TOF MS identification [18].
Methods
Chemicals and reagents
Generic chemicals were purchased from Sigma-Aldrich
(St. Louis, USA), while reagents for 2D-DIGE were pur-
chased from GE Healthcare (Uppsala, Sweden). All pri-
mary antibodies were purchased from Genetex (Hsinchu,
Taiwan) and anti-mouse, and anti-rabbit secondary anti-
bodies were purchased from GE Healthcare (Uppsala,
Sweden). All the chemicals and biochemicals used in this
study were of analytical grade.
Cell lines and cell culture
The rat cardiomyocyte cell line H9C2 was purchased from
American Type Culture Collection (ATCC) (Manassas,
VA) and was maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% (v/v) FCS,
L-glutamine (2 mM), streptomycin (100 μg/mL) and
penicillin (100 IU/mL) (all from Gibco-Invitrogen Corp.,
UK). Cells were incubated in a humidified incubator at
37°C and 5% CO2. and passaged at 80-90% confluence
by trypsinization according to standard procedures.
MTT cell viability assay
The detailed MTT experimental procedure has been
described in our previous study [19].
Immunofluorescence
Cells were plated onto coverslips (VWR international)
for overnight incubation and subsequently fixed with PBS
containing 4% (v/v) paraformaldehyde for 25 min. After
washing three times in PBS, samples were permeabilized
in PBS containing 0.2% (v/v) Triton X-100 for 10 min. and
then rinsed and blocked in PBS containing 5% (w/v) BSAfor 10 min prior to incubate with primary antibodies
diluted in 2.5% BSA/PBS for 1 h. After PBS washings,
samples were incubated with the appropriate fluores-
cently labeled secondary antibodies diluted in 2.5%
BSA/PBS for 1 h. Samples were then washed three times
with PBS and briefly rinsed with ddH2O twice before
applying to Vectashield mounting medium (Vector Lab).
Coverslip edges were sealed with nail polish onto glass
slides (BDH) and then air-dried in the dark at 4°C. For
image analysis, cells were visualized using a Zeiss Axiovert
Z1 fluorescent microscope (Carl Zeiss Inc., Germany).
Identical laser intensities were used to detect the same
immunostained proteins to obtain non-saturated im-
ages. Images were exported as .tif files using the Zeiss
Axioversion 4.0.
Flow cytometry analysis for apoptosis detection
Annexin-V/propidium iodide (PI) double assay was per-
formed using the Annexin V, Alexa Fluor® 488 Conjugate
Detection kit (Life technologies). Following doxorubicin
treatment, cells were typsinized from culture dish and
washed twice with cold PBS. 1 × 106 cells were resus-
pended in 500 μL binding buffer and stained with 5 μL
Alexa Fluor 488 conjugated annexin V according to the
manufacturer’s instructions. 1 μL 100 μg/mL propidium
iodide (PI) was mixed gently to cells for 15 min at room
temperature in the dark. After incubation period, sam-
ples were subjected to FCM analysis in 1 h. using BD
Accuri C6 Flow Cytometry (BD Biosciences, San Jose,
CA). The data were analyzed using Accuri CFlow@ and
CFlow Plus analysis software (BD Biosciences).
Immunoblotting analysis
Immunoblotting analysis was used to validate the diffe-
rential abundance of mass spectrometry identified proteins.
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Figure 2 (See legend on next page.)
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Figure 2 Effects of quercetin on doxorubicin-induced changes of cell viability, cell apoptosis and cell morphology in H9C2 cells.
(A) MTT-based viability assays were performed on H9C2 cell cultures following treatments with different concentrations of quercetin (50 μM, 100 μM,
150 μM and 200 μM) or left untreated. Values were normalized against untreated samples and were the average of 4 independent
measurements +/- the standard deviation. The statistic analysis was performed with two group paired Student t-test. (B) Typical dot plot diagrams
detected annexin V-FITC and PI staining represent untreated, doxorubicin-treated, and quercetin-pretreated followed by doxorubicin–treated cells. The
x-axis and y-axis stand for the intensity of annexin V-FITC and PI, respectively. The lower left area of presented background staining by annexin V-FITC
and PI in normal cells, and apoptotic signals located in the right area. This figure is representative of 4 replicates. The statistic analysis of the replicates
was listed in right panel. (C) The levels of caspase 3 and caspase 9 in H9C2 cells were detected by immunoblotting. GAPDH served as a sample loading
control. (D) Cell morphology and protein location of F-actin in H9C2 cells were analyzed by immunostaining. H9C2 cells on coverslips were either left
untreated, treated with doxorubicin or pre-treated with quercetin prior to doxorubicin treatment before fixation and staining. F-actin was stained with
phalloidin and nuclei were stained with DAPI. Each set of five fields were taken using the same exposure and images are representative of five
different fields. In (B) ~ (D), H9C2 cells were untreated, 0.45 μM of doxorubicin for 24 h, or 100 μM of quercetin for 4 h followed by 0.45 μM of
doxorubicin for 24 h.
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for expression validation were purchased from Genetex
(Hsinchu, Taiwan).
2D-DIGE, gel image analysis, protein staining, in-gel
digestion and MALDI-TOF MS analysis
The detailed experimental procedures have been described
in our previous publications [23-25]. Notably, peaks in
the mass range of m/z 800-3000 were used to generate a
peptide mass fingerprint that was searched against the
Swiss-Prot/TrEMBL database (released on August 2011)
with 531473 entries using Mascot software v2.3.02 (Matrix
Science, London, UK). The parameters used for Mascot
search are listed: mouse; tryptic digest with a maximum
of 1 missed cleavage; carbamidomethylation of cysteine,
partial protein N-terminal acetylation, partial methio-
nine oxidation and partial modification of glutamine
to pyroglutamate and a mass tolerance of 50 ppm.
Identification was accepted based on significant MASCOT
Mowse scores (p < 0.05), spectrum annotation and ob-
served versus expected molecular weight and pI on 2-DE
as well as at least 5 peptides in each identified protein.
Results
Quercetin facilitates cell survival and maintains cell
morphology in doxorubicin-induced cell death in H9C2 cells
To evaluate the effect of doxorubicin on rat cardiomyo-
cytes (H9C2), we exposed the cells to doxorubicin in a
range of 0-1 μM for 24 h in a serum-free medium. After
exposure to doxorubicin, dose dependent loss of cell via-
bilities was observed in the H9C2 cells in 3 independent
experiments using MTT assays (Figure 1). At a concen-
tration of 0.45 μM, a significant loss (50%) of cell viability
was detected after 24 h. To verify the role of quercetin
regarding the recovery of doxorubicin-induced cardio-
myopathy, we investigated the changes in cell viability
in the H9C2 cells incubated in 0 μM, 50 μM, 100 μM,
150 μM and 200 μM quercetin for 4 h, followed by 24
h-exposure to 0.45 μM doxorubicin. Our results dem-
onstrated that cell viability was significantly improvedusing quercetin in concentrations from 50 to 200 μM
(Figure 2A).
Because excess ROS stress from doxorubicin-treated
cardiomyocyte alters redox homeostasis and induces cell
death, cell apoptosis was further detected using FACS.
During cell apoptosis, phosphatidylserine is translocated
to the outer surface of the plasma membrane, which has
a high affinity to annexin V-FITC, and PI can penetrate
the cell nucleus. As shown in Figure 2B, the apoptotic
rate increased from 4.9% to 61.4% after doxorubicin
treatment, whereas the apoptotic rate decreased to 9.5%
after the H9C2 cells were pretreated with quercetin before
doxorubicin treatment. In addition, the levels of the pro-
teolytic enzymes, caspase 9 and caspase 3, were detected
using immunoblotting in control, doxorubicin-treated
and quercetin-pretreated H9C2 cells. Figure 2C indi-
cates increased expression levels of the apoptosis factors
for caspase 3 and caspase 9 after doxorubicin treatment.
Quercetin protected the H9C2 cells from doxorubicin-
induced cell injury by inhibiting the expressions of cas-
pase 3 and caspase 9. Additionally, immunostained images
of F-actin indicated that doxorubicin treatment affected
cytoskeletal protein reorganization, causing cell morph-
ology alternation (Figure 2D). Therefore, quercetin pre-
treatment is essential to maintaining doxorubicin-induced
morphological changes.
2D-DIGE analysis of untreated and doxorubicin-treated
H9C2 cells and quercetin pretreatment followed by
doxorubicin treatment
To fully understand the roles of doxorubicin and quer-
cetin pretreatment in H9C2 cells, lysates of cells untreated,
treated with doxorubicin, or treated with doxorubicin after
pretreatment of quercetin, were subjected to 2D-DIGE
analysis. The results of the 2D-DIGE analysis and DeCyder
processing identified 2156 protein spots, and 73 proteins
exhibited differential expression (≧ 1.5 fold or ≦-1.5
fold; p < 0.05) among the 3 conditions (Figure 3). Additional
file 1: Table S1 shows the 73 proteins that were identified
using MALDI-TOF MS, and 31 of the 73 identified
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Figure 3 (See legend on next page.)
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Figure 3 2D-DIGE analysis of H9C2 cells in response to doxorubicin treatment and pre-treatment with quercetin. (A) Samples arrangement
for a triplicate 2D-DIGE experiment. (B) Protein samples (100 μg each) were labeled with Cy-dyes and separated using 24 cm, pH 3-10 non-linear IPG
strips. 2D-DIGE images of the protein samples from H9C2 cells in response to doxorubicin treatment and pre-treatment with quercetin at appropriate
excitation and emission wavelengths were shown as well as overlaid pseudo-colored images processed with ImageQuant Tool (GE Healthcare)
(C). (D) Protein samples (100 μg each) purified from total cell lysates were labeled with Cy-dyes and separated using 24 cm, pH 3-10 non-linear
IPG strips. The differentially expressed protein features were annotated with spot numbers. In this 2D-DIGE experiment, H9C2 cells were untreated,
0.45 μM of doxorubicin for 24 h, or 100 μM of quercetin for 4 h followed by 0.45 μM of doxorubicin for 24 h.
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teration can be reversed by pretreating with quercetin
(Additional file 1: Table S1 and Additional file 2). For
example, the 78 kDa glucose-regulated protein (GRP-78)
(No.444) was up-regulated (1.63 fold) in the doxorubicin-
treated cells, whereas quercetin reduced the overexpres-
sion of doxorubicin-treated GRP-78 (-1.85 fold). TheB
A
Figure 4 Percentage of total differentially expressed proteins identif
doxorubicin treatment and pre-treatment with quercetin accordingresult suggested that the protective mechanisms of quer-
cetin significantly altered the levels of chaperone proteins
during doxorubicin-treatment in the cardiomyocytes.
Figure 4A shows the functional distribution of the
identified proteins from the 2D-DIGE results. Most of
the proteins identified using MALDI-TOF MS were
associated with the cytoskeletal element and cell migrationied by 2D-DIGE/MALDI-TOF MS for H9C2 cells in response to







































































































































































































































































































































































































































































































































Figure 5 (See legend on next page.)
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Figure 5 Representative immunoblotting analyses for selected differentially expressed proteins identified by proteomic analysis of
H9C2 cells in response to doxorubicin treatment and pre-treatment with quercetin. The levels of identified proteins, (A) Aconitase,
(B) ATP synthase, (C) Carbonic anhydrase, (D) GRP78, (E) HSP27, (F) HSP60, (G) Peroxiredoxin 6, (H) Tropomyosin 4, (I) Vimmentin, in H9C2 cells
in response to doxorubicin treatment and pre-treatment with quercetin were confirmed by immunoblot, while GAPDH was used as loading
controls (left panels). The protein expression maps and two-dimensional spot images were shown in right panels and middle panels, respectively.
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that quercetin is crucial for sustaining cytoskeletal
and metabolic alternations responding to oxidative
damage in the cardiomyocytes. During doxorubicin-
mediated cardiomyopathy, the majority of the identified
proteins were located in the cytoplasm and the nucleus
(Figure 4B).Verifying the 2D-DIGE results by using immunoblotting
and immunostaining
The levels of aconitase, ATP synthase, carbonic anhydrase,
GRP78, HSP27, HSP60, peroxiredoxin 6, tropomyosin 4,
vimmentin and cofilin-1 were examined using immu-
noblotting and immunostaining to validate the results
of the 2D-DIGE analysis. The results indicated that
aconitase, ATP synthase, GRP78, HSP60, peroxiredoxin
6, tropomyosin 4 and cofilin-1 were overexpressed in
response to doxorubicin. However, quercetin suppressed
the expression of the proteins during doxorubicin treatment
in the H9C2 cells (Figure 5 and Figure 6). These results




Figure 6 Representative immunofluorescent analyses for Cofilin ident
doxorubicin treatment and pre-treatment with quercetin. H9C2 cells in
anti-Cofilin-1 antibody (Red) and stained with Phalloidin (Green). Nucleus w
the same exposure, and images are representative of three different fields.
with 0.45 μM doxorubicin for 24 h or pretreated with 100 μM quercetin forDiscussion
Myocardial damage induced by doxorubicin was pri-
marily caused by chelating DNA, inhibiting topoisomerase
II and producing free radicals. Based on these concepts,
numerous studies have evaluated the effects of doxorubicin-
induced toxicity and the mechanisms that contribute to
protecting cardiomyocytes [26-28]. In our previous stud-
ies, we reported on the cellular oxidative targets during
heart damage induced by doxorubicin [29]. Additionally,
we demonstrated that quercetin might dephosphorylate
Src kinase activity in ROS-induced H9C2 cells and block
ROS-induced inflammatory responses through STAT3
kinase. These activities contribute to preventing ische-
mia and reperfusion injury in cardiomyocytes [30]. In
this study, we determined that quercetin treatment pro-
tected cardiomyocytes in the doxorubicin-induced heart
damage model. Moreover, quercetin significantly facili-
tated cell survival by inhibiting cell apoptosis and main-
taining cell morphology by inducing cytoskeletal protein
rearrangement. Furthermore, after the proteomic analysis,
we observed dramatic reductions in the H9C2 proteins
involving protein folding, redox-regulation, and energyCofilin-1 Merge
ified by proteomic analysis of H9C2 cells in response to
different treatment conditions were fixed and incubated with
as stained with DAPI (Blue). Each set of three fields was taken using
In this validation experiment, H9C2 cells were left untreated, treated
4 h followed by 0.45 μM doxorubicin for further 24 h.
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involving cytoskeleton and cytoskeleton regulatory pro-
teins among the lysates of cells that were untreated,
treated with doxorubicin, or treated with doxorubicin
after pretreatment with quercetin. We suggest that car-
diomyocytes develop defense mechanisms to overcome
doxorubicin-induced ROS accumulation, which causes
cell damage and cell death. The defense mechanisms
include the overexpression of redox-modulated proteins
to scavenge doxorubicin-induced ROS. In this study, pre-
treating with quercetin might scavenge ROS, diminishing
oxidative stress and subsequently downregulating redox-
regulatory proteins including glutamate dehydrogenase 1,
isocitrate dehydrogenase, NADP-dependent malic enzyme,
retinal dehydrogenase 1 and peroxiredoxin-6.
Moreover, we also observed that most proteins critical
for modulating protein folding were down-regulated dur-
ing pretreatment with quercetin which might account for
the decreased concentrations of ROS causing the decrease
of incorrectly folding proteins and attenuating the expres-
sion of chaperone proteins such as 60 kDa heat shock
protein, 78 kDa glucose-regulated protein, alpha-crystallin
B, heat shock protein beta-1, Stress-induced-phosphoprotein
1 and T-complex protein 1. Similar results have been re-
ported in ethanol- and arsenite-induced oxidative stress,
which caused over-expression of anti-oxidative stress
proteins. However, the over-expression was significantly
alleviated by quercetin pre-treatment [31,32]. In addition
to these studies, the quercetin-induced downregulation of
the protective proteins might account for the quercetin-
treated cells exhibiting higher sensitivity to ROS damage,
such as cancer cells [33,34]. Several key regulatory pro-
teins mediated the interaction of heat shock proteins to
inhibit apoptosis. The intrinsic pathway of caspase-mediated
apoptosis was stimulated by c-Jun kinase, resulting in the
release of cytochrome c from the mitochondria, and the
subsequent activation of a caspase cascade involving cas-
pase 8 and caspase 3. They were each inhibited by heat
shock cognate 71, which interacted with Bcl-2 through
Bag-1, enabling the complex to be incorporated into the
mitochondrial membrane to inhibit apoptosis [35]. In this
study, heat shock cognate 71 was upregulated in the
quercetin-pretreated H9C2 cells, implying that heat shock
cognate 71 is essential for protecting H9C2 cells from
doxorubicin-induced apoptosis.
Quercetin was also observed to modulate the expression
of cytoskeletal proteins (e.g., tubulins) and migration-
regulated proteins (e.g., tubulin polymerization-promoting
proteins) after encountering doxorubicin-induced damage
[36]. Our immunofluorescence study demonstrated that
quercetin can promote F-actin organization. Proteomic
data also suggested that actin molecules were overex-
pressed during quercetin pretreatment, implying that
quercetin causes the efficient regulation of protrusiondynamics and the wound healing of doxorubicin-damaged
cardiomyocytes.
Our proteomic analysis indicated that quercetin pre-
treatment might down-regulate the levels of proteins in-
volving energy metabolism including mitochondrial ATP
synthesis, glycolytic proteins and TCA cycle proteins.
Similar results were also reported by Dihal et al., who
observed that glycolytic proteins were significantly down-
regulated in their report. Additionally, Shoshan et al.
reported that quercetin can modulate mitochondrial
energy production by interacting with ATP synthase
and blocking the enzyme’s activity [37,38]. The current
proteomic analysis corresponded with these results.
Our preliminary data indicated that quercetin reduces
but enhances the cytotoxicity of doxorubicin on cardio-
myocyte H9C2 cells and liver cancer HepG2 cells, re-
spectively (data not shown). This observation suggested
the potential of combining quercetin and doxorubicin
for treating liver cancer. Although no direct evidence
indicates the cooperative effect of quercetin and doxo-
rubicin on other cancer treatment, performing relevant
evaluations of other cancers is worthwhile in the future.
In summary, this study is the first to report on the
principle mechanism of quercetin against doxorubicin-
induced cytotoxicity in cardiomyocytes, using cell biology
and a quantitative proteomic analysis. The information
obtained in this study presents the potential of combining
quercetin with doxorubicin to achieve reduced cardio-
toxicity in cancer chemotherapy.Conclusions
This study is the first to report detailed protective mecha-
nisms for the action of quercetin against doxorubicin-
induced cardiomyocyte toxicity. Quercetin might stimulate
cardiomyocytes to repair damage after treating doxorubicin
by modulating metabolic activation, protein folding and
cytoskeleton rearrangement.
Additional files
Additional file 1: Table S1. Differentially expressed proteins were
listed alphabetically after 2D-DIGE and MALDI-TOF Mass spectrometry
analysis in H9C2 cells in response to doxorubicin treatment and quercetin
pretreatment. The average ratios of these 73 spots are differentially
expressed among untreated (control), doxorubicin-treated and
quercetin-pretreated followed by doxorubicin-treated cells, calculated
from triplicate gels.
Additional file 2: Raw spectra of the identified proteins from
Additional file 1: Table S1.
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